Nine Chapters Capital Management’s Repros Therapeutics Inc. RPRX Stock Holding History

Nine Chapters Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-41,700	Closed	-$298K	–	1373
2015 Q2	$298K	Buy	+41,700	New	+$325K	0.03%	720
2015 Q1	–	Sell	-31,300	Closed	-$312K	–	1307
2014 Q4	$312K	Sell	31,300 -4,900	-14%	-$41.8K	0.03%	665
2014 Q3	$358K	Buy	+36,200	New	+$536K	0.03%	648

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DCM

Destrier Capital Management New York $144M AUM 7.28% 1-Year Est. Return

Nine Chapters Capital Management's RPRX Position: Q3 2015 in Review

Nine Chapters Capital Management sold out of Repros Therapeutics Inc. (RPRX) in Q3 2015, closing a stake of 41,700 shares — an estimated $298K sold.

Nine Chapters Capital Management first reported a position in RPRX in Q3 2014 and held it in 3 quarters. The position peaked at $358K in Q3 2014. 58 funds tracked by Wall St. Rank hold RPRX as of Q3 2015.

Nine Chapters Capital Management reported no remaining Repros Therapeutics Inc. position as of Q3 2015 after selling out during the quarter.
Nine Chapters Capital Management sold 41,700 Repros Therapeutics Inc. shares in Q3 2015, an estimated $298K.
Nine Chapters Capital Management first reported a position in Repros Therapeutics Inc. in Q3 2014 and held it in 3 quarters.
Nine Chapters Capital Management's Repros Therapeutics Inc. position peaked at $358K in Q3 2014.
58 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q3 2015.

Based on Nine Chapters Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.